companydata.dkAmicus Therapeutics ApS: Financial statements 2023
CVR: 39359340
Amicus Therapeutics ApS (CVR 39359340) has filed annual accounts for 2023. In 2023, the company reported a gross profit of DKK 1,732,212 and a net result of DKK 52,221 compared with DKK 54,033 the year before. That is an increase of 9.9% compared with the year before. Equity amounted to DKK 355,314. The solvency ratio was 48.4%. The company had 1 employee in the financial year.
- Gross Profit
- 1,732,212 kr.
- Profit/Loss
- 52,221 kr.
- Equity
- 355,314 kr.
- Total Assets
- 734,055 kr.
- Employees
- 1
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2023 | - | 1.7 mio. | 52 t. | 355 t. | 1 |
| 2022 | - | 1.6 mio. | 54 t. | 303 t. | 1 |
| 2021 | - | 644 t. | 19 t. | 249 t. | 1 |
| 2020 | - | 490 t. | 22 t. | 230 t. | 1 |
| 2019 | - | 2 mio. | 84 t. | 208 t. | 2 |
Fetch this data via API
Every Danish company, financial statement and ownership record — straight into your own systems or your AI assistant via MCP.
See the API documentationEvents in 2023
Amicus Therapeutics ApS has published its annual report for 2022. Gross profit came to DKK 1,575,511, and the net result was DKK 54,033.
As of May 24, 2023, Charlotte Ann Galvin has joined the board of directors of Amicus Therapeutics ApS.
As of May 24, 2023, Charlotte Ann Galvin is registered as director of Amicus Therapeutics ApS.
As of March 17, 2023, John Erik Mattias Bankel has left the board of directors of Amicus Therapeutics ApS.
As of March 17, 2023, John Erik Mattias Bankel has stepped down as director of Amicus Therapeutics ApS.
About Amicus Therapeutics ApS
Amicus Therapeutics ApS is a Danish company of the type Anpartsselskab based in København V, founded in 2018. The company is registered under the industry Engroshandel med medicinalvarer og sygeplejeartikler. The management consists of Richard Gideon Morris. The company is owned by Amicus Therapeutics UK Ltd.. The company has 2 employees. In 2025, the company reported a gross profit of DKK 1,441,140 and a net result of DKK 115,004 compared with DKK 16,475 the year before. Equity amounted to DKK 424,641.